RxDoctor Payments DataLook up a doctor →

George Atallah, DO

Interventional Pain Medicine · Houston, TXNPI 1093940694

Payments from drug & device makers

$48,088in general payments, 2019–2025

Across 1,002 payments — averaging $47.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$31K
  • Nevro Corp.$3K
  • AbbVie$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • Collegium Pharmaceutical, Inc.$1K
  • Pfizer$934
  • plus $8K from 47 others

What the payments were for

  • Speaking & faculty fees$25,32353%
  • Travel & lodging$2,1544%
  • Food & beverage$20,58343%
  • Education$290%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$48,088 in reported general payments places this provider in the 85th percentile of 287 interventional pain medicine providers in Texas.

See all interventional pain medicine providers in Texas

Medicare billing

Part B allowed, 2024
$614,029
Medicare patients
284
Services billed
22,089

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RelistorMethylnaltrexone Bromide27$62,398
Nurtec OdtRimegepant Sulfate23$43,623
NucyntaTapentadol Hcl55$36,443
BelbucaBuprenorphine Hcl33$32,505
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,103$28,673
LyricaPregabalin17$24,218
Buprenorphine92$20,680
Pregabalin748$16,172
OxycontinOxycodone Hcl20$12,287
Lidocaine132$11,999
Nucynta ErTapentadol Hcl18$11,077
ZtlidoLidocaine24$8,589
Xtampza ErOxycodone Myristate14$8,301
Gabapentin538$7,484
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen266$6,885

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Nucynta, Belbuca, Nucynta Er, Xtampza Er$1,194$88,327120 claims
PfizerNurtec Odt, Lyrica$934$67,84140 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$1,595$62,39827 claims
Scilex Pharmaceuticals Inc.Ztlido$581$8,58924 claims
Redhill Biopharma Inc.Movantik$117$6,25015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 287 interventional pain medicine providers in Texas.

Other interventional pain medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →